Want to join the conversation?
$BAX said it has closed CE marking in the European Union for the expanded indication of the ready-to-use surgical patch Hemopatch. Hemopatch is now approved in the European Union for use in closing dural defects including excision, retraction or shrinkage of the dura mater following traumatic injury.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?